Pharmaceutical Preparations · NJ · CIK 200406
Johnson & Johnson researches, manufactures, and sells a broad range of healthcare products
Comparable business profile · signals at a glance
Coverage (30d): 2 reputable articles · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Feb 27, 2026: 7 sold $80.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 | Decker Robert JVP Corporate Controller | Sell | 4,075 | $247.87 | $1.0M |
| Feb 20, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $325K |
| Feb 18, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Sell | 13,625 | $244.20 | $3.3M |
| Feb 18, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Sell | 8,998 | $244.53 | $2.2M |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO | Sell | 33,386 | $242.75 | $8.1M |
| Feb 17, 2026 | Reed John CEVP, Innovative Medicine, R&D | Sell | 29,927 | $243.00 | $7.3M |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO | Sell | 24,961 | $242.68 | $6.1M |
| Feb 17, 2026 | Reed John CEVP, Innovative Medicine, R&D | Sell | 21,721 | $243.00 | $5.3M |
| Feb 17, 2026 | Swanson James D.EVP, CIO | Sell | 20,521 | $242.70 | $5.0M |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO | Sell | 19,241 | $242.99 | $4.7M |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO | Sell | 12,066 | $242.87 | $2.9M |
| Feb 17, 2026 | Broadhurst VanessaEVP, Global Corp Affairs | Sell | 6,197 | $243.39 | $1.5M |
| Feb 17, 2026 | Reed John CEVP, Innovative Medicine, R&D | Sell | 2,283 | $243.00 | $555K |
| Feb 13, 2026 | Swanson James D.EVP, CIO | Sell | 22,191 | $243.71 | $5.4M |
| Feb 13, 2026 | Swanson James D.EVP, CIO | Sell | 19,368 | $243.76 | $4.7M |
| Jan 26, 2026 | Duato JoaquinCEO and Chairman of the Board | Sell | 51,218 | $220.99 | $11.3M |
| Jan 26, 2026 | Duato JoaquinCEO and Chairman of the Board | Sell | 48,782 | $221.48 | $10.8M |
| Nov 26, 2025 | Morikis John GDirector | Buy | 1,250 | $206.15 | $258K |
| Oct 17, 2025 | Reed John CEVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
12 added · 3 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.